PremiumCompany AnnouncementsAstraZeneca Deepens Real-World Safety Check on Eplontersen for Amyloidosis11h agoAZN
PremiumRatingsAstraZeneca: Buy Rating Reaffirmed on Robust Pipeline and Attractive Valuation; Price Target Unchanged at $16,50015h agoAZN
AstraZeneca: Buy Rating Reaffirmed on Robust Pipeline and Attractive Valuation; Price Target Unchanged at $16,500
PremiumCompany AnnouncementsHSBC Declares Second Interim Dividend for 2026 with Multi-Currency Payout15h ago
PremiumCompany AnnouncementsHSBC Sets Second Interim Dividend for 2026 and Details Currency Conversions15h ago